# Retatrutide Type: Product Source: GetYourBrief — https://getyourbrief.com/entity/retatrutide Canonical HTML page: https://getyourbrief.com/entity/retatrutide ## Timeline - **2027**: Regulatory Submissions — Expected window for the first triple-agonist drug applications to the FDA. - **2026-06-23**: STAT News publishes exposé — Citing three anonymous sources, STAT reports the compassionate use approval and notes that top health officials took an unusual interest, prompting speculation the patient was 'well connected.' The outlet asked the White House about Trump's possible involvement due to demographic overlap. - **2026-06-23**: White House denial — Same day, White House spokesman Kush Desai denies on X that the application was for President Trump, with other officials calling the reporting false. They do not confirm the patient's identity. - **2026-04**: Compassionate use request submitted — A senior NIH clinician seeks FDA and Eli Lilly permission for a 79-year-old man to receive retatrutide to treat refractory obesity, obstructive sleep apnea, and pulmonary hypertension. - **2026-02-24**: Novo Triple-G Phase 2 — Novo Nordisk reports nearly 20% weight loss at 26 weeks. - **2026**: Phase 3 Expansion — Anticipated start of Novo Nordisk's pivotal late-stage clinical program. - **2023-Q2**: Lilly Retatrutide Phase 2 — Eli Lilly releases data showing 17.5% weight loss at 24 weeks. ## Recent coverage (8 stories, network-wide) ### White House Denies 79-Year-Old Trump Received Early Access to Lilly's Retatrutide Under Compassionate Use 2026-06-25 12:26:11 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 The White House denied that President Trump is the 79-year-old patient granted compassionate use of Lilly’s investigational weight-loss drug retatrutide, intensifying scrutiny over equity and transparency in the FDA’s expanded access program for experimental obesity treatments. Full story: https://gethealthbrief.com/story/white-house-denies-trump-early-access-retatrutide ### RBC Bullish on Eli Lilly's Retatrutide Despite Mixed Trial Data 2026-03-20 05:29:58 · Sector: finance · Sentiment: Neutral · Impact: 7/10 · Sources: 2 RBC Capital maintains a positive outlook on Eli Lilly, identifying Retatrutide as a primary growth engine for the pharmaceutical giant. Despite recent mixed clinical trial results, analysts believe the drug's triple-agonist mechanism offers a significant competitive edge in the global obesity market. Full story: https://getfinancebrief.com/story/rbc-capital-eli-lilly-retatrutide-growth-analysis ### RBC Capital Backs Eli Lilly’s Retatrutide as Next-Gen Obesity Powerhouse 2026-03-20 05:29:24 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 2 RBC Capital has reaffirmed its bullish outlook on Eli Lilly’s Retatrutide, identifying the triple-agonist as a primary long-term growth driver despite mixed clinical trial data. Analysts suggest that the drug's unprecedented weight-loss efficacy will likely overshadow manageable safety concerns, securing Lilly's dominance in the metabolic health sector. Full story: https://getbiobrief.com/story/eli-lilly-retatrutide-rbc-capital-growth-driver ### Eli Lilly’s Retatrutide Positioned as Next-Gen Obesity Powerhouse by RBC Capital 2026-03-20 05:27:44 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 2 RBC Capital reaffirms Eli Lilly’s Retatrutide as a critical future growth engine, despite recent mixed clinical trial data. The triple-agonist therapy is expected to redefine the weight-loss market by offering superior efficacy compared to existing dual-agonist treatments. Full story: https://gethealthbrief.com/story/eli-lilly-retatrutide-rbc-capital-growth-driver ### Lilly’s Retatrutide Shows 1.9% A1c Drop, Trailing Mounjaro in Phase 3 2026-03-19 11:58:23 · Sector: bio · Sentiment: Positive · Impact: 8/10 · Sources: 2 Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 trial for type 2 diabetes. While the results are clinically significant, they appear to slightly trail the top-line efficacy of Lilly's own blockbuster Mounjaro, shifting the industry focus toward the drug's potential for superior weight loss. Full story: https://getbiobrief.com/story/lilly-retatrutide-phase-3-diabetes-data ### Lilly’s Triple-G Retatrutide Hits Phase 3 Diabetes Goal, Lags Mounjaro Slightly 2026-03-19 11:58:18 · Sector: health · Sentiment: Positive · Impact: 8/10 · Sources: 2 Eli Lilly's triple-agonist retatrutide achieved a 1.9% reduction in blood sugar levels in its first Phase 3 diabetes trial, a result that matches or slightly trails the performance of its own blockbuster Mounjaro. While the glucose-lowering data is robust, the market's primary interest remains focused on the drug's potential for industry-leading weight loss and metabolic benefits. Full story: https://gethealthbrief.com/story/lilly-triple-g-phase-3-diabetes-data ### Novo Nordisk Triple-G Agonist Hits 20% Weight Loss in Phase 2 Trial 2026-02-24 12:08:43 · Sector: bio · Sentiment: Neutral · Impact: 7/10 · Sources: 2 Novo Nordisk's experimental triple-G agonist demonstrated nearly 20% weight loss in a 26-week Phase 2 trial, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's mid-stage results, Novo remains on track to reach the market after its rival. Full story: https://getbiobrief.com/story/novo-nordisk-triple-g-obesity-trial-results ### Novo Nordisk Triple-G Agonist Challenges Eli Lilly in Obesity Market 2026-02-24 12:06:06 · Sector: health · Sentiment: Neutral · Impact: 7/10 · Sources: 2 Novo Nordisk's midstage trial for its 'triple-G' agonist demonstrated nearly 20% weight loss in patients after 26 weeks, positioning it as a potent competitor to Eli Lilly’s retatrutide. While the efficacy data appears slightly superior to Lilly's midstage results, Novo remains behind in the clinical timeline, likely reaching the market second. Full story: https://gethealthbrief.com/story/novo-nordisk-triple-g-obesity-trial-results --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.